On March 6, 2019, Beijing Novo Nordisk China's R&D Center announced that it would launch the INNOVO platform and cooperate with local innovation forces in the biomedical field to contribute actively to the innovation campaign aiming to accelerate the medicine and health development in Beijing.
In the meantime, it is YEERAN's honor and tremendous encouragement that its products and services have been acknowledged by leading pharmaceutical companies around the world.
We appreciate Novo Nordisk (China) Pharmaceutical Co., Ltd.'s trust for VINNO medical ultrasonography for small animals.
Novo Nordisk is a world's leading biopharmaceutical company that is committed to the health of human beings and benefiting patients, doctors, and society with advanced biotechnologies. Over the past 80 plus years, it has become a frontrunner in the diabetes treatment in the world with its unrivaled R&D strength.
Novo Nordisk (China) Pharmaceutical Co., Ltd. was established in 2994 and is the first biopharmaceutical that has established an R&D center in China.